Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes
Tier: Tier 1

1. A 38-year-old woman with no prior medical history has office BP of 158/96 mmHg on two correctly performed visits. She takes only a progestin-only oral contraceptive and has no symptoms or family history of hypertension. Her physician wants to start antihypertensive therapy immediately. What should happen first?

A) Start amlodipine 5 mg immediately because two Stage 2 readings on separate visits satisfy the diagnostic requirement for pharmacotherapy
B) Order plasma metanephrines and aldosterone-to-renin ratio (ARR) because all patients under 40 require secondary cause exclusion before any antihypertensive is prescribed
C) Refer to nephrology because primary hypertension is unlikely in a 38-year-old woman and specialist evaluation is mandatory before drug therapy
D) Perform ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) before initiating pharmacotherapy to confirm sustained hypertension and exclude white coat hypertension, which affects approximately 15–30% of patients with elevated office readings — initiating drug therapy in white coat hypertension exposes the patient to unnecessary adverse effects without cardiovascular benefit
E) Switch her contraceptive to a combined estrogen-containing formulation to confirm whether estrogen-mediated angiotensinogen upregulation is driving her BP before committing to drug therapy

ANSWER: D

Rationale:

Option D is correct: ABPM or HBPM should confirm sustained hypertension before initiating pharmacotherapy in a patient without compelling indications, because white coat hypertension affects 15–30% of patients with elevated office readings.

Option A: Option A is incorrect — pharmacotherapy before confirming sustained hypertension risks treating a white coat effect.
Option B: Option B is incorrect — secondary cause screening is triggered by specific clinical clues such as hypokalemia, young lean patients without risk factors, or resistance to multiple agents — not universally required before any antihypertensive.
Option C: Option C is incorrect — primary hypertension occurs in patients under 40, particularly with office-confirmed readings.
Option E: Option E is incorrect — she is already on a progestin-only contraceptive containing no estrogen; switching to a combined pill would add estrogen and worsen BP through angiotensinogen upregulation.

2. A 61-year-old man with confirmed hypertension, type 2 diabetes, urine ACR (albumin-to-creatinine ratio) of 95 mg/g, and eGFR of 58 mL/min/1.73m² has serum potassium 4.3 mEq/L. Which antihypertensive drug class is most specifically indicated by this combination of findings and why?

A) A thiazide diuretic — natriuresis reduces albuminuria directly and volume reduction is the dominant mechanism of hypertension in diabetic CKD
B) A beta-blocker — SNS (sympathetic nervous system) overactivation drives hypertension in metabolic syndrome and beta-1 blockade most directly addresses this mechanism
C) A dihydropyridine CCB (calcium channel blocker) — L-type calcium channel blockade in the afferent arteriole reduces hyperfiltration and is first-line for proteinuric diabetic nephropathy
D) A mineralocorticoid receptor antagonist such as spironolactone — aldosterone-mediated podocyte injury is the dominant mechanism of diabetic proteinuria
E) An ACE inhibitor or ARB — RAAS blockade reduces intraglomerular pressure through efferent arteriole vasodilation, providing renal protection in diabetic nephropathy and reducing albuminuria beyond what BP lowering alone achieves, supported by multiple landmark CKD outcome trials

ANSWER: E

Rationale:

Option E is correct: ACE inhibitors and ARBs reduce intraglomerular pressure through efferent arteriole vasodilation, providing renal protection in diabetic nephropathy independent of BP lowering — the compelling indication created by CKD with proteinuria.

Option A: Option A is incorrect — thiazides are useful antihypertensives but do not provide the specific intraglomerular pressure reduction or renal protective mechanism.
Option B: Option B is incorrect — SNS overactivation contributes to hypertension in metabolic syndrome but does not define the first-line agent in diabetic CKD with proteinuria.
Option C: Option C is incorrect — dihydropyridine CCBs dilate the afferent arteriole and can worsen intraglomerular pressure without concurrent RAAS blockade; they are not first-line for proteinuric diabetic nephropathy.
Option D: Option D is incorrect — mineralocorticoid receptor antagonists are useful add-on agents but not first-line ahead of RAAS inhibitors in this clinical scenario.

3. A 49-year-old woman with resistant hypertension has ARR (aldosterone-to-renin ratio) of 55 with suppressed renin and spontaneous hypokalemia. Confirmatory oral sodium loading is ordered. Which of the following correctly identifies the result that confirms autonomous aldosterone secretion on this test, and why?

A) 24-hour urinary aldosterone greater than 12 mcg/day after 3 days of high oral sodium intake — autonomous aldosterone from primary aldosteronism cannot be suppressed by sodium and volume loading, while normal aldosterone is suppressed; failure to suppress above this threshold confirms the diagnosis
B) Plasma aldosterone below 6 ng/dL after oral sodium loading — autonomous aldosterone is paradoxically suppressed by sodium in primary aldosteronism, confirming the diagnosis
C) Plasma renin activity above 2 ng/mL/hr after 3 days of high sodium intake — renin stimulation by sodium loading confirms autonomous renin secretion as the underlying mechanism
D) 24-hour urinary free cortisol above the upper limit of normal — this confirms that cortisol excess rather than aldosterone excess is driving the hypertension and hypokalemia
E) Plasma aldosterone above 10 ng/dL before sodium loading begins — the pre-loading baseline aldosterone level alone is diagnostic without requiring a formal suppression test

ANSWER: A

Rationale:

Option A is correct: oral sodium loading raises sodium and volume, which normally suppresses aldosterone through baroreceptor and macula densa feedback; autonomous aldosterone secretion in primary aldosteronism cannot be suppressed, and 24-hour urinary aldosterone greater than 12 mcg/day after 3 days of high sodium intake confirms the diagnosis.

Option B: Option B is incorrect — autonomous aldosterone is not suppressed below 6 ng/dL; that is the threshold for the IV saline infusion test (plasma aldosterone remaining above 6 ng/dL after saline confirms autonomy), not oral sodium loading.
Option C: Option C is incorrect — renin stimulation by sodium loading does not confirm primary aldosteronism; renin is the denominator of the ARR and its behavior after sodium loading is not the relevant endpoint.
Option D: Option D is incorrect — urinary free cortisol screens for Cushing syndrome, a different secondary cause from primary aldosteronism.
Option E: Option E is incorrect — a single baseline aldosterone level without suppression testing has insufficient specificity to confirm autonomous secretion.

4. A 72-year-old man with hypertension, a 50 pack-year smoking history, and creatinine 2.1 mg/dL has BP of 172/94 mmHg resistant to three antihypertensives. Renal Doppler shows high-velocity turbulent flow bilaterally in both renal arteries. His cardiologist recommends adding lisinopril as a fourth agent. Which of the following most accurately addresses this recommendation?

A) Adding lisinopril is appropriate because RAAS blockade targets the elevated Ang II driving the renovascular hypertension directly at its source and the renal protective benefit outweighs the risk
B) The Doppler findings are likely artifactual in an elderly smoker; lisinopril can be started with standard potassium and creatinine monitoring
C) Lisinopril can be used at a reduced dose of 2.5 mg with close monitoring because the hemodynamic risk in bilateral renal artery stenosis is dose-dependent and avoided at sub-therapeutic doses
D) The creatinine of 2.1 mg/dL confirms the kidneys have already sustained irreversible damage and lost their efferent tone dependence; RAAS inhibition is safe at this level of renal impairment
E) Lisinopril and all RAAS inhibitors are contraindicated in bilateral renal artery stenosis — GFR maintenance in both kidneys depends on Ang II-mediated efferent arteriole constriction; RAAS blockade removes this compensatory mechanism bilaterally, precipitating acute kidney injury

ANSWER: E

Rationale:

Option E is correct: in bilateral renal artery stenosis, reduced perfusion pressure in both kidneys makes GFR maintenance on both sides dependent on Ang II-mediated efferent arteriole constriction; RAAS blockade removes this compensatory mechanism and precipitates acute bilateral kidney injury.

Option A: Option A is incorrect — while RAAS blockade does target Ang II, the renal consequence in bilateral stenosis is AKI that outweighs any BP benefit.
Option B: Option B is incorrect — bilateral high-velocity turbulent Doppler signals with resistant hypertension and CKD in a high-risk patient are a genuine clinical finding requiring serious evaluation, not dismissal.
Option C: Option C is incorrect — the hemodynamic risk is not dose-dependent in the clinically relevant range; even low-dose RAAS inhibition removes efferent tone.
Option D: Option D is incorrect — existing CKD does not eliminate efferent tone dependence; it typically increases the risk of further RAAS inhibitor-induced AKI.

5. A 44-year-old woman with type 2 diabetes and urine ACR 62 mg/g has office BP of 128/82 mmHg on two visits. Her physician considers her normotensive and proposes no antihypertensive therapy. HBPM over 7 days shows an average of 138/88 mmHg. Which of the following most accurately interprets this discrepancy and identifies the correct management?

A) The HBPM average of 138/88 mmHg, above the HBPM threshold of ≥135/85 mmHg, with normal office readings, identifies masked hypertension — a phenotype that carries cardiovascular and renal risk equivalent to sustained hypertension; in a diabetic patient with microalbuminuria this is a compelling indication for antihypertensive therapy including RAAS blockade
B) The higher home readings reflect the stress of self-measurement; office readings obtained by a trained professional are more reliable and management should be based on those
C) The discrepancy is within expected day-to-day BP variability and does not represent a clinically meaningful phenotype; no change in management is needed
D) HBPM readings are systematically elevated compared to office readings in diabetic patients due to autonomic dysfunction; the home threshold of 138/88 mmHg is within the normal range for this population
E) The HBPM average of 138/88 mmHg meets Stage 2 hypertension criteria by HBPM standards; immediate triple combination antihypertensive therapy is indicated

ANSWER: A

Rationale:

Option A is correct: normal office BP with HBPM average ≥135/85 mmHg defines masked hypertension — a phenotype with cardiovascular and renal risk equivalent to sustained hypertension; in a diabetic patient with microalbuminuria this finding mandates antihypertensive therapy.

Option B: Option B is incorrect — home readings obtained with validated devices using the standard protocol are more representative of true BP burden than office readings subject to white coat effect; the dismissal is clinically incorrect.
Option C: Option C is incorrect — the discrepancy identifies a specific phenotype with established management implications, not random variability.
Option D: Option D is incorrect — HBPM does not have a higher threshold for diabetic patients due to autonomic dysfunction; ≥135/85 mmHg is the standard threshold.
Option E: Option E is incorrect — HBPM of 138/88 mmHg exceeds the ≥135/85 mmHg threshold by a small margin and represents Stage 1 equivalent, not Stage 2; triple therapy from the outset is not indicated.

6. A 55-year-old woman with hypertension has ABPM showing daytime mean 134/82 mmHg (below the ≥135/85 mmHg daytime threshold) but nighttime mean 138/86 mmHg (above the ≥120/70 mmHg nighttime threshold), with a nighttime-to-daytime BP ratio showing nighttime BP higher than daytime BP — a 3% nighttime dip. Which of the following most accurately characterizes this pattern and its clinical implications?

A) Her daytime ABPM is below the diagnostic threshold for hypertension; the nighttime elevation is an expected physiological rise that does not require clinical action
B) This pattern represents white coat hypertension because the daytime ABPM is normal; no treatment is needed and repeat ABPM in one year is appropriate
C) Isolated nocturnal hypertension is a normal variant in perimenopausal women; the threshold of ≥120/70 mmHg at night is set too low and her values should be interpreted against age-adjusted reference ranges
D) Her nighttime BP exceeds the ABPM nighttime threshold of ≥120/70 mmHg and she is a reverse-dipper (nighttime BP higher than daytime BP), a pattern independently associated with substantially elevated cardiovascular risk — particularly stroke and LVH (left ventricular hypertrophy); this warrants investigation for secondary causes of nocturnal hypertension such as OSA (obstructive sleep apnea) and consideration of bedtime antihypertensive dosing
E) The 3% nighttime dip represents mild non-dipping, which only becomes clinically significant when the dip is completely absent (0%); a 3% dip requires no specific management

ANSWER: D

Rationale:

Option D is correct: her nighttime mean (138/86 mmHg) exceeds the ABPM nighttime threshold (≥120/70 mmHg) and her pattern is reverse-dipping (nighttime BP higher than daytime BP), independently associated with substantially elevated cardiovascular risk particularly for stroke and LVH.

Option A: Option A is incorrect — normal daytime ABPM does not negate the clinical significance of elevated nighttime readings above the established nighttime threshold.
Option B: Option B is incorrect — white coat hypertension requires elevated office BP with normal out-of-office BP overall; this pattern involves elevated nighttime BP and does not fit that definition.
Option C: Option C is incorrect — reverse dipping is not a normal variant in any age or sex group; the nighttime threshold of ≥120/70 mmHg reflects validated cardiovascular outcome data and is not adjusted for age or menopausal status.
Option E: Option E is incorrect — non-dipping becomes clinically significant at below 10% nocturnal dip; 3% is severely non-dipping and reverse dipping is the most concerning variant, not a mild finding.

7. A 29-year-old woman at 32 weeks of gestation has BP of 156/104 mmHg on two readings 4 hours apart, 2+ proteinuria, frontal headache, platelets 138,000/μL, and AST 58 U/L. Severe preeclampsia is diagnosed and IV labetalol is initiated for acute BP control. Which of the following agents should be simultaneously administered for a purpose distinct from blood pressure lowering?

A) IV furosemide to reduce cerebral edema and prevent progression to eclampsia through diuresis-mediated reduction of intracranial pressure
B) IV dexamethasone to treat the maternal systemic inflammatory response driving the preeclampsia and simultaneously mature fetal lungs
C) IV magnesium sulfate for seizure prophylaxis — magnesium acts as a physiological calcium antagonist at the NMDA receptor, reducing neuronal excitability and preventing progression to eclampsia; it does not meaningfully lower BP and its indication is neuroprotective, not antihypertensive
D) Oral nifedipine immediate-release to add a second antihypertensive mechanism through calcium channel blockade in parallel with labetalol
E) IV phenytoin for seizure prophylaxis, which is preferred over magnesium sulfate in proteinuric preeclampsia because it crosses the placenta less readily and carries lower fetal risk

ANSWER: C

Rationale:

Option C is correct: IV magnesium sulfate is administered simultaneously with antihypertensive therapy in severe preeclampsia specifically for seizure prophylaxis through NMDA receptor antagonism reducing neuronal excitability — its purpose is neuroprotective, not antihypertensive, and it does not meaningfully lower BP.

Option A: Option A is incorrect — furosemide is not used for eclampsia prophylaxis; volume depletion in preeclampsia can compromise uteroplacental perfusion.
Option B: Option B is incorrect — corticosteroids may be given for fetal lung maturity in preterm gestation but are not treatment for the maternal inflammatory cascade of preeclampsia.
Option D: Option D is incorrect — nifedipine immediate-release is an acceptable acute antihypertensive in pregnancy but is not given "for a purpose distinct from BP lowering."
Option E: Option E is incorrect — phenytoin is not preferred over magnesium sulfate for eclampsia prophylaxis; magnesium is the evidence-based standard of care with superior efficacy in randomized trials.

8. A 47-year-old man with hypertension, gout, and CKD stage 3a (eGFR 52 mL/min/1.73m²) has serum uric acid 8.9 mg/dL on allopurinol. His physician wants to add a thiazide diuretic for volume control. Which of the following most accurately describes the relevant pharmacological concern and the most appropriate alternative?

A) Thiazide diuretics are safe in this patient because allopurinol completely neutralizes any uricosuric or anti-uricosuric effect of thiazides through xanthine oxidase inhibition
B) The primary concern with thiazides in gout is hypokalemia-mediated triggering of acute attacks; potassium supplementation eliminates this risk and thiazides can be safely used
C) Thiazide diuretics lose efficacy below eGFR 45 mL/min/1.73m² and should be replaced with loop diuretics in all patients with CKD stage 3a regardless of other considerations
D) Thiazide diuretics raise serum uric acid by competing with urate at the proximal tubular organic anion secretion transporter, reducing urate excretion; in a patient with gout and already-elevated uric acid on allopurinol this risks precipitating acute gout attacks; losartan is a preferred alternative because in addition to antihypertensive and renal protective effects it has a unique uricosuric property through URAT1 (proximal tubular urate reabsorption transporter) inhibition — lowering serum uric acid rather than raising it
E) Losartan should be avoided as the alternative because ARBs competitively inhibit allopurinol metabolism through CYP2C9, raising allopurinol plasma levels and increasing the risk of allopurinol hypersensitivity syndrome

ANSWER: D

Rationale:

Option D is correct: thiazides raise serum uric acid by reducing proximal tubular urate secretion, worsening hyperuricemia and risking gout attacks; losartan is the preferred alternative because it lowers serum uric acid through URAT1 inhibition — a property unique among ARBs.

Option A: Option A is incorrect — allopurinol inhibits xanthine oxidase (reducing urate synthesis) but does not neutralize thiazide-mediated reduction in tubular urate secretion; these are independent mechanisms.
Option B: Option B is incorrect — the uric acid-raising effect of thiazides is the primary concern in a patient with gout, not hypokalemia-mediated attacks; potassium supplementation does not address urate accumulation.
Option C: Option C is incorrect — thiazides retain meaningful efficacy in CKD stage 3a (eGFR 52); significantly reduced efficacy occurs at approximately eGFR <30 mL/min/1.73m².
Option E: Option E is incorrect — losartan does not inhibit allopurinol metabolism through CYP2C9; this pharmacokinetic interaction is fabricated.

9. A 63-year-old man with hypertension and three calcium oxalate kidney stones in 5 years requires antihypertensive intensification. BP is 152/94 mmHg. Which antihypertensive drug class provides a pharmacological benefit specifically relevant to his nephrolithiasis, and what is the mechanism?

A) ACE inhibitors — RAAS blockade reduces glomerular filtration pressure, lowering the filtered calcium load and reducing urinary calcium concentration
B) Beta-blockers — renin suppression reduces aldosterone, which decreases calcium excretion through mineralocorticoid receptor-mediated mechanisms in the collecting duct
C) Loop diuretics such as furosemide — blockade of the Na-K-2Cl cotransporter in the thick ascending limb reduces calcium reabsorption at that segment, redirecting it to the distal tubule where it is completely reabsorbed, producing net hypocalciuria
D) ARBs — AT1 (angiotensin type 1) receptor blockade in the proximal tubule directly stimulates calcium-ATPase activity, increasing calcium reabsorption from tubular fluid
E) Thiazide diuretics — blockade of the Na-Cl cotransporter (NCC) in the distal convoluted tubule reduces intracellular sodium in tubular epithelial cells, stimulating the basolateral Na-Ca exchanger to increase calcium reabsorption from tubular fluid, producing hypocalciuria that reduces urinary calcium available for stone formation

ANSWER: E

Rationale:

Option E is correct: thiazides produce hypocalciuria through NCC blockade — reduced intracellular sodium stimulates the basolateral Na-Ca exchanger, increasing calcium reabsorption from tubular fluid and reducing urinary calcium available for calcium oxalate stone formation.

Option A: Option A is incorrect — ACE inhibitors do not meaningfully reduce urinary calcium through the filtered load mechanism at therapeutic doses.
Option B: Option B is incorrect — beta-blockers do not reduce urinary calcium excretion through aldosterone-mediated collecting duct mechanisms in the manner described.
Option C: Option C is incorrect — loop diuretics increase urinary calcium excretion (calciuresis) by blocking calcium reabsorption in the thick ascending limb; they worsen hypercalciuric nephrolithiasis and are not indicated here.
Option D: Option D is incorrect — ARBs do not directly stimulate calcium-ATPase through AT1 receptor blockade in the proximal tubule; this mechanism is fabricated.

10. A 58-year-old man with hypertension on two antihypertensives has polysomnography-confirmed severe OSA (obstructive sleep apnea) with apnea-hypopnea index 48 events per hour. He starts CPAP (continuous positive airway pressure) therapy. Which of the following most accurately sets expectations for CPAP's effect on his blood pressure?

A) CPAP will fully normalize his BP within 4 weeks in patients with severe OSA, eliminating the need for antihypertensive medications in most cases
B) CPAP produces a modest average systolic BP reduction of approximately 2–3 mmHg — meaningful at a population level but insufficient to normalize BP in a patient already requiring two antihypertensives; pharmacological therapy must continue and likely requires intensification, with mineralocorticoid receptor antagonists being particularly effective in OSA-associated resistant hypertension due to concurrent aldosterone excess
C) CPAP has no effect on blood pressure; its cardiovascular benefit is limited to improved oxygenation and reduced daytime somnolence
D) CPAP lowers BP by approximately 10–15 mmHg systolic in severe OSA, equivalent to adding a second antihypertensive agent
E) CPAP is contraindicated in patients on antihypertensive medications because positive airway pressure combined with vasodilatory agents causes dangerous nocturnal hypotension

ANSWER: B

Rationale:

Option B is correct: CPAP produces a modest average systolic BP reduction of approximately 2–3 mmHg — real but insufficient to normalize BP in a patient already requiring two antihypertensives; pharmacological therapy must continue, and mineralocorticoid receptor antagonists are specifically effective in OSA-associated resistant hypertension because they address the concurrent aldosterone excess that CPAP incompletely corrects.

Option A: Option A is incorrect — CPAP rarely eliminates the need for antihypertensives; the neurohormonal drivers of hypertension in OSA persist beyond what CPAP fully corrects.
Option C: Option C is incorrect — CPAP does produce a real though modest antihypertensive effect.
Option D: Option D is incorrect — a 10–15 mmHg reduction grossly overstates the average antihypertensive effect of CPAP.
Option E: Option E is incorrect — CPAP is not contraindicated with antihypertensive medications; there is no clinically significant pharmacodynamic interaction.

11. A 34-year-old woman with hypertension has plasma free metanephrines confirming pheochromocytoma (normetanephrine 4.8 nmol/L, metanephrine 2.2 nmol/L, both >3× upper limit of normal) and CT shows a 3.8 cm right adrenal mass. She is referred for adrenalectomy. Which of the following correctly describes the required preoperative pharmacological preparation?

A) Begin a beta-blocker first for 5–7 days to control the tachycardia and palpitations that are the most dangerous perioperative risk, then add an alpha-blocker if BP remains uncontrolled closer to surgery
B) No preoperative pharmacological preparation is needed in an asymptomatic patient with a unilateral tumor; intraoperative hemodynamic management with IV phentolamine is sufficient
C) Begin IV phentolamine infusion for the entire preoperative period because its short-acting profile provides the safest continuous protection against catecholamine surges before surgery
D) Begin calcium channel blockers alone as the primary preoperative agent — they block catecholamine-mediated vasoconstriction without the rebound hypertension risk of alpha-blockers
E) Begin phenoxybenzamine or doxazosin (oral alpha-blockade) first for 10–14 days preoperatively with high-sodium diet and fluid loading to expand contracted intravascular volume; add a beta-blocker only after adequate alpha-blockade is established to control tachycardia; beta-blockade before alpha-blockade risks catastrophic hypertensive crisis from unopposed alpha-1 vasoconstriction during catecholamine surges

ANSWER: E

Rationale:

Option E is correct: alpha-blockade must precede beta-blockade — the non-negotiable sequencing rule — because beta-blockers given first remove beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction from catecholamines unopposed, risking a lethal hypertensive crisis during intraoperative tumor manipulation.

Option A: Option A is incorrect — beginning with a beta-blocker first violates the non-negotiable sequencing rule and risks precisely the catastrophic hypertensive crisis that preoperative preparation is designed to prevent.
Option B: Option B is incorrect — preoperative pharmacological preparation is mandatory regardless of symptom status; intraoperative manipulation without preparation carries substantial mortality risk.
Option C: Option C is incorrect — IV phentolamine is reserved for intraoperative hypertensive surges; sustained oral alpha-blockade (phenoxybenzamine or doxazosin) is used for outpatient preoperative preparation.
Option D: Option D is incorrect — CCBs may be used as adjuncts or alternatives in alpha-blocker-intolerant patients but are not the standard primary preoperative agent in current guidelines.

12. A 67-year-old man with hypertension controlled on amlodipine and lisinopril starts celecoxib (a selective COX-2 inhibitor) for knee osteoarthritis. Three weeks later BP is 178/106 mmHg and creatinine has risen from 1.0 to 1.4 mg/dL. Which of the following most accurately explains the mechanism and guides management?

A) Celecoxib causes hypertension through direct alpha-1 adrenergic receptor activation; the creatinine rise is unrelated and represents natural CKD progression independent of the new medication
B) Selective COX-2 inhibitors are renal-safe in patients on ACE inhibitors because ACE inhibitor-mediated bradykinin accumulation compensates for prostaglandin loss in the afferent arteriole — the creatinine rise reflects a different process
C) The creatinine rise confirms celecoxib-induced acute interstitial nephritis, which is distinct from the hemodynamic BP mechanism; immediate corticosteroid therapy is required for both conditions
D) CCBs such as amlodipine develop pharmacokinetic tachyphylaxis from long-term use; the celecoxib is not contributing to BP or creatinine changes and should be continued while the CCB is changed
E) Selective COX-2 inhibitors share the same renal mechanism as non-selective NSAIDs — inhibiting PGE2 (prostaglandin E2) and PGI2 (prostacyclin) synthesis in the kidney — causing afferent arteriolar vasoconstriction, sodium retention, and blunting of RAAS inhibitor efficacy; the creatinine rise confirms hemodynamically significant reduction in renal perfusion; celecoxib should be discontinued and acetaminophen substituted

ANSWER: E

Rationale:

Option E is correct: selective COX-2 inhibitors share the renal prostaglandin-depleting mechanism of non-selective NSAIDs — inhibiting PGE2 and PGI2 causes afferent arteriolar vasoconstriction, sodium retention, and blunting of RAAS inhibitor and diuretic efficacy; the creatinine rise confirms hemodynamically significant renal impairment requiring drug discontinuation.

Option A: Option A is incorrect — COX-2 inhibitors do not cause hypertension through alpha-1 receptor activation; the renal prostaglandin mechanism is well established.
Option B: Option B is incorrect — bradykinin accumulation from ACE inhibition does not compensate for prostaglandin loss in the afferent arteriole; these are independent pathways, and COX-2 inhibitors remain nephrotoxic in patients on ACE inhibitors.
Option C: Option C is incorrect — hemodynamic AKI from COX-2 inhibitor use is not acute interstitial nephritis and does not require corticosteroids; the treatment is discontinuation of the offending drug.
Option D: Option D is incorrect — CCBs do not develop pharmacokinetic tachyphylaxis; the temporal correlation with celecoxib initiation is the pharmacologically plausible explanation.

13. A 52-year-old man with hypertension presents with 8 kg weight gain over 8 months, easy bruising, proximal muscle weakness, and new glucose intolerance. Cushing syndrome is suspected. Which of the following most accurately describes the pharmacological mechanism by which cortisol excess causes hypertension?

A) Excess cortisol directly activates cardiac beta-1 adrenergic receptors, raising heart rate and cardiac output as the primary driver of hypertension in Cushing syndrome
B) Excess cortisol inhibits aldosterone synthesis through negative feedback on the zona glomerulosa, and hypertension results entirely from the paradoxical sodium loss that follows
C) Excess cortisol activates mineralocorticoid receptors (cortisol has intrinsic mineralocorticoid activity at high concentrations), potentiates vascular Ang II sensitivity, increases hepatic angiotensinogen production, and stimulates the SNS (sympathetic nervous system) — producing sodium retention, vasoconstriction, and volume-dependent hypertension through multiple simultaneous pathways
D) Excess cortisol inhibits renal prostaglandin synthesis through COX (cyclooxygenase) suppression in renal epithelial cells, producing the same afferent arteriolar vasoconstriction and sodium retention mechanism as NSAIDs
E) Excess cortisol causes hypertension exclusively through visceral adiposity accumulation, which drives leptin-mediated SNS activation as the sole mechanism; cortisol itself has no direct vascular or renal pressor effects

ANSWER: C

Rationale:

Option C is correct: cortisol excess causes hypertension through multiple simultaneous mechanisms — mineralocorticoid receptor activation at high cortisol concentrations (producing sodium retention and potassium wasting), potentiation of vascular Ang II sensitivity, increased hepatic angiotensinogen production expanding the RAAS substrate, and direct SNS stimulation.

Option A: Option A is incorrect — cortisol does not directly activate cardiac beta-1 receptors as the primary pressor mechanism in Cushing syndrome.
Option B: Option B is incorrect — cortisol excess does not suppress aldosterone synthesis through negative feedback; rather, cortisol itself has intrinsic mineralocorticoid activity at high concentrations, and aldosterone is not suppressed to the point of sodium loss.
Option D: Option D is incorrect — cortisol does not cause hypertension through COX suppression and renal prostaglandin depletion; this NSAID mechanism is not how glucocorticoids raise BP.
Option E: Option E is incorrect — while adiposity is a contributing factor in some patients, cortisol has direct vascular and renal pressor effects that cause hypertension even in patients with minimal weight gain.

14. A 41-year-old woman with biochemically confirmed primary aldosteronism (ARR 52, positive confirmatory saline infusion test) has bilateral 1.5–2 cm adrenal nodules on CT. Which of the following most accurately describes the next step and why adrenal CT findings alone are insufficient to determine management?

A) Bilateral nodules on CT confirm bilateral adrenal hyperplasia as the subtype; proceed directly to medical management with spironolactone without further imaging
B) Bilateral nodules confirm bilateral adrenocortical carcinoma; urgent surgical referral for bilateral adrenalectomy is required
C) Adrenal CT has an approximately 40% error rate in distinguishing a unilateral aldosterone-producing adenoma from bilateral adrenal hyperplasia — bilateral nodules may represent bilateral hyperplasia or an adenoma in one adrenal with an incidentaloma in the other; adrenal vein sampling (AVS) is required in most surgical candidates to accurately lateralize aldosterone excess before any decision about adrenalectomy versus long-term medical therapy
D) Bilateral nodules on CT in a 41-year-old woman confirm familial hyperaldosteronism type 1; genetic testing for the chimeric CYP11B1/CYP11B2 gene should be performed and glucocorticoid suppression therapy started immediately
E) The diagnosis of primary aldosteronism has been biochemically confirmed; adrenal CT findings are irrelevant and management should proceed directly to spironolactone titration without any imaging or lateralization studies

ANSWER: C

Rationale:

Option C is correct: adrenal CT has approximately 40% error rate in lateralizing primary aldosteronism because it cannot reliably distinguish a unilateral aldosterone-producing adenoma from bilateral hyperplasia, and incidentalomas in one adrenal coexisting with hyperplasia in the other are common; AVS is required before surgical decisions.

Option A: Option A is incorrect — CT alone cannot confirm bilateral hyperplasia as the subtype; bilateral nodules are consistent with several possibilities and AVS is needed to lateralize.
Option B: Option B is incorrect — bilateral adrenal nodules in the context of confirmed primary aldosteronism without additional malignant imaging features are not indicative of adrenocortical carcinoma.
Option D: Option D is incorrect — familial hyperaldosteronism type 1 is suggested by onset before age 20 or strong family history, not simply by bilateral nodules in a 41-year-old; this is not the standard next step.
Option E: Option E is incorrect — adrenal CT and lateralization by AVS are essential steps before committing to medical versus surgical management; the approach to treatment differs substantially between unilateral adenoma (potentially curative adrenalectomy) and bilateral hyperplasia (long-term medical therapy).

15. A 58-year-old man with hypertension and prior MI has BP well-controlled on metoprolol 50 mg and amlodipine 5 mg. Duloxetine (an SNRI — serotonin-norepinephrine reuptake inhibitor) is started for neuropathic pain. Which of the following most accurately describes the pharmacological risk and the appropriate monitoring?

A) Duloxetine carries no cardiovascular risk in hypertensive patients because serotonin reuptake inhibition counteracts the noradrenergic pressor effect, producing a neutral net BP impact
B) Duloxetine inhibits neuronal norepinephrine reuptake at moderate to higher doses, increasing synaptic norepinephrine concentrations; the resulting alpha-1 receptor activation in resistance arterioles raises systemic vascular resistance and BP in a dose-dependent manner; BP should be monitored after initiation and with dose escalation, and antihypertensive adjustment may be required
C) Duloxetine is absolutely contraindicated in patients with a prior MI because SNRI-mediated norepinephrine excess causes coronary vasospasm through alpha-1 receptor activation in coronary arteries
D) Duloxetine's BP risk arises through serotonin-mediated platelet activation causing thromboxane A2-mediated vasoconstriction; aspirin co-administration eliminates this mechanism
E) Duloxetine is safe in hypertensive patients on metoprolol because beta-1 blockade prevents any norepinephrine-mediated BP elevation by blocking the cardiac component of the pressor response

ANSWER: B

Rationale:

Option B is correct: duloxetine inhibits the norepinephrine transporter (NET) at moderate to higher doses, raising synaptic norepinephrine and activating alpha-1 receptors in resistance arterioles — increasing systemic vascular resistance and BP in a dose-dependent manner that requires BP monitoring.

Option A: Option A is incorrect — serotonin reuptake inhibition does not neutralize the noradrenergic pressor effect; these operate through separate receptor pathways.
Option C: Option C is incorrect — SNRIs are not categorically contraindicated post-MI; the mechanism is systemic vascular resistance elevation through alpha-1 activation, not coronary vasospasm.
Option D: Option D is incorrect — duloxetine's BP risk is noradrenergic (alpha-1-mediated vasoconstriction), not serotonin-mediated platelet activation; aspirin does not address this mechanism.
Option E: Option E is incorrect — metoprolol's beta-1 blockade reduces heart rate and cardiac output but does not block alpha-1-mediated peripheral vasoconstriction from elevated norepinephrine; systemic vascular resistance can still rise.

16. A 45-year-old woman with hypertension develops severe headache, blurred vision, and confusion. In the emergency department BP is 226/148 mmHg, she is disoriented, and funduscopy shows bilateral papilledema and flame hemorrhages. Creatinine is 2.8 mg/dL with red cell casts on urinalysis. Which of the following identifies the correct immediate BP management target and explains why rapid normalization is explicitly contraindicated?

A) Reduce BP to below 120/80 mmHg within 30 minutes using IV sodium nitroprusside — the most rapid and complete normalization prevents the greatest degree of irreversible target organ injury
B) Administer IV furosemide immediately as the first agent to reduce intravascular volume and lower BP through diuresis before any vasodilator is considered
C) Reduce mean arterial pressure (MAP) by approximately 10–25% in the first hour using a titratable IV agent such as labetalol or nicardipine; more rapid normalization is explicitly contraindicated because organs adapted to chronic hypertension have upward-shifted autoregulatory ranges — precipitous BP reduction below the autoregulatory threshold causes ischemic injury to the brain, kidneys, and coronary circulation
D) Avoid antihypertensive treatment until CT head excludes intracranial hemorrhage; then reduce BP to normal over 72 hours using oral agents
E) Reduce BP to below 160/90 mmHg within 15 minutes because papilledema indicates impending transtentorial herniation requiring immediate decompressive BP reduction

ANSWER: C

Rationale:

Option C is correct: in hypertensive emergency, the target is MAP reduction of approximately 10–25% in the first hour using a titratable IV agent; rapid normalization is contraindicated because chronic hypertension upward-shifts cerebral and renal autoregulatory ranges — reducing BP precipitously below the autoregulatory threshold causes ischemic injury to organs adapted to high perfusion pressure.

Option A: Option A is incorrect — normalizing to below 120/80 mmHg within 30 minutes is the wrong target and wrong timeline; it would cause ischemic injury.
Option B: Option B is incorrect — IV furosemide is not the preferred first-line agent for hypertensive emergency with encephalopathy; titratable IV vasodilators provide better acute control of the vascular resistance driving the crisis.
Option D: Option D is incorrect — this is a hypertensive emergency requiring immediate IV treatment; waiting for CT before treating and using oral agents are both inadequate and would cause irreversible injury.
Option E: Option E is incorrect — papilledema in hypertensive emergency reflects breakthrough of cerebrovascular autoregulation, not transtentorial herniation; a 15-minute timeline to near-normal BP is too aggressive and dangerous.